Sight Sciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $466.6M
- Price
- $8.47
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.05%
- Volume
- 233.5K
About
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Quick stats
Shares outstanding55.1M
Computed float55.1M
Float / shares100.0%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001531177
AI Summary
AI-generated1/18
minorbullishproduct launch
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Sight Sciences announced commercial availability of the OMNI Ultra Surgical System, the latest generation of its implant-free ab interno canaloplasty glaucoma platform, to be showcased at the AAO annual meeting October 9-12 in New Orleans.
OMNI Ultra enables single-pass canaloplasty followed by trabeculotomy with TruSync Plus technology and enhanced catheter visualization, targeting all three areas of aqueous outflow resistance for adult primary open-angle glaucoma patients.
The company will also preview the Clearance Assistant Plus tool for use with its TearCare dry eye system at the meeting.